董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Scott Canute | 男 | Director | 58 | 30.78万美元 | 未持股 | 2018-10-29 |
| Behzad Aghazadeh | 男 | Director | 47 | 31.92万美元 | 1771.45 | 2018-10-29 |
| Michael Pehl | 男 | Director,President and Chief Executive Officer | 54 | 358.34万美元 | 未持股 | 2018-10-29 |
| Khalid Islam | 男 | Director | 62 | 31.88万美元 | 未持股 | 2018-10-29 |
| Peter Barton Hutt | 男 | Director | 83 | 29.47万美元 | 未持股 | 2018-10-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kurt Andrews | 男 | Chief Human Resources Officer | 49 | 未披露 | 未持股 | 2018-10-29 |
| Michael Pehl | 男 | Director,President and Chief Executive Officer | 54 | 358.34万美元 | 未持股 | 2018-10-29 |
| Usama Malik | 男 | Chief Business Officer and interim Chief Financial Officer | 44 | 未披露 | 未持股 | 2018-10-29 |
| Robert Iannone | 男 | Head of Research & Development and Chief Medical Officer | 51 | 292.40万美元 | 未持股 | 2018-10-29 |
| Morris Rosenberg | 男 | Chief Technology Officer | 59 | 243.63万美元 | 1.50 | 2018-10-29 |
| Brendan P. Delaney | 男 | Chief Commercial Officer | 43 | 146.75万美元 | 未持股 | 2018-10-29 |
| Jared Freedberg | 男 | General Counsel | 50 | 未披露 | 未持股 | 2018-10-29 |
董事简历
中英对照 | 中文 | 英文- Scott Canute
-
Scott Canute ，他担任我们的董事会成员（2011年10月以来）。他也曾担任Moderna Therapeutics公司（物理治疗公司）的技术咨询委员会的成员（2012年10月以来），也曾担任Proteon Therapeutics公司（生物制药公司）的董事会成员（2015年7月以来），以及Flexion Therapeutics公司（一家制药公司）的董事会成员（2015年3月以来）。此外，他此前曾担任Inspiration Biopharmaceuticals公司（生物制药公司）的董事会成员（从2012年9月到2013年9月）、AlloCure公司（一个生物科技公司）的董事会成员（从2012年10月到2014年10月）。2010年3月至2011年7月，他曾担任Genzyme Corporation（生物技术公司）的总裁，负责全球制造业和企业运营。此前，他曾担任Eli Lilly and Company的多种管理职务（从1982年到2007年），包括全球制造运营总裁（2004年至2007年）、全球制造副总裁（从2001年到2004年）、全球医药制造业副总裁（1999年至2001年）、欧洲制造业务总经理（1998年至1999年）。他持有哈佛大学商学院 （ Harvard Business School）的工商管理硕士学位，以及the University of Michigan的化学工程学士学位。
Scott Canute has served as a member of our board of directors since October 2011. Mr. Canute also has served as a member of the board of directors of Immunomedics, Inc., a biopharmaceutical company, since March of 2017 and of Akebia Therapeutics, Inc., a biopharmaceutical company, since August 2016 and of Proteon Therapeutics, Inc., a biopharmaceutical company, since July 2015 and of Flexion Therapeutics, Inc., a pharmaceutical company, since March 2015. In addition, Mr. Canute formerly served as a member of the board of directors of Inspiration Biopharmaceuticals, Inc., a biopharmaceutical company, from September 2012 to September 2013 and AlloCure Inc., a biotechnology company, from October 2012 to October 2014 and as a member of the technical advisory board of Moderna Therapeutics, Inc., a physical therapy company, from October 2012 to March 2017. From March 2010 to July 2011 Mr. Canute served as the President of Global Manufacturing and Corporate Operations of Genzyme Corporation, a biotechnology company. Prior to that, from 1982 to 2007 Mr. Canute served in various management positions at Eli Lilly & Company, including as the President of Global Manufacturing Operations from 2004 to 2007 Vice President of Global Manufacturing from 2001 to 2004 Vice President of Global Pharmaceutical Manufacturing from 1999 to 2001 and General Manager of European Manufacturing Operations from 1998 to 1999. Mr. Canute received an M.B.A. from Harvard Business School and a B.S. in Chemical Engineering from the University of Michigan. - Scott Canute ，他担任我们的董事会成员（2011年10月以来）。他也曾担任Moderna Therapeutics公司（物理治疗公司）的技术咨询委员会的成员（2012年10月以来），也曾担任Proteon Therapeutics公司（生物制药公司）的董事会成员（2015年7月以来），以及Flexion Therapeutics公司（一家制药公司）的董事会成员（2015年3月以来）。此外，他此前曾担任Inspiration Biopharmaceuticals公司（生物制药公司）的董事会成员（从2012年9月到2013年9月）、AlloCure公司（一个生物科技公司）的董事会成员（从2012年10月到2014年10月）。2010年3月至2011年7月，他曾担任Genzyme Corporation（生物技术公司）的总裁，负责全球制造业和企业运营。此前，他曾担任Eli Lilly and Company的多种管理职务（从1982年到2007年），包括全球制造运营总裁（2004年至2007年）、全球制造副总裁（从2001年到2004年）、全球医药制造业副总裁（1999年至2001年）、欧洲制造业务总经理（1998年至1999年）。他持有哈佛大学商学院 （ Harvard Business School）的工商管理硕士学位，以及the University of Michigan的化学工程学士学位。
- Scott Canute has served as a member of our board of directors since October 2011. Mr. Canute also has served as a member of the board of directors of Immunomedics, Inc., a biopharmaceutical company, since March of 2017 and of Akebia Therapeutics, Inc., a biopharmaceutical company, since August 2016 and of Proteon Therapeutics, Inc., a biopharmaceutical company, since July 2015 and of Flexion Therapeutics, Inc., a pharmaceutical company, since March 2015. In addition, Mr. Canute formerly served as a member of the board of directors of Inspiration Biopharmaceuticals, Inc., a biopharmaceutical company, from September 2012 to September 2013 and AlloCure Inc., a biotechnology company, from October 2012 to October 2014 and as a member of the technical advisory board of Moderna Therapeutics, Inc., a physical therapy company, from October 2012 to March 2017. From March 2010 to July 2011 Mr. Canute served as the President of Global Manufacturing and Corporate Operations of Genzyme Corporation, a biotechnology company. Prior to that, from 1982 to 2007 Mr. Canute served in various management positions at Eli Lilly & Company, including as the President of Global Manufacturing Operations from 2004 to 2007 Vice President of Global Manufacturing from 2001 to 2004 Vice President of Global Pharmaceutical Manufacturing from 1999 to 2001 and General Manager of European Manufacturing Operations from 1998 to 1999. Mr. Canute received an M.B.A. from Harvard Business School and a B.S. in Chemical Engineering from the University of Michigan.
- Behzad Aghazadeh
-
Behzad Aghazadeh，我们的董事会主席，是Venbio精选基金的管理合伙人和投资组合经理。
Behzad Aghazadeh, our Chairman of the Board of Directors, is a Managing Partner and Portfolio Manager of the venBio Select Fund. - Behzad Aghazadeh，我们的董事会主席，是Venbio精选基金的管理合伙人和投资组合经理。
- Behzad Aghazadeh, our Chairman of the Board of Directors, is a Managing Partner and Portfolio Manager of the venBio Select Fund.
- Michael Pehl
-
Michael Pehl在血液学和肿瘤学方面拥有超过20年的经验，并在该领域推出了多款重磅药物，包括Revlimid，Pomalyst和Abraxane。在2017年12月加入Immunomedics之前，Pehl先生在新基医药公司工作了11年，担任德国总经理，Vice President中欧，血液学欧洲主管，随后担任全球营销主管，最后担任血液学和肿瘤学总裁。此前，他曾任职Amgen公司14年，在那里他曾担任德国肿瘤学、风湿病和肾脏学以及瑞士Amgen Europe公司的多种商业领导职务。Pehl先生在德国慕尼黑大学（Ludwig-Maximilians-University Munich）获得分子生物学文凭。
Michael Pehl has more than 20 years of experience in hematology and oncology and has launched multiple blockbuster drugs in that space including Revlimid, Pomalyst, and Abraxane. Prior to joining Immunomedics in December 2017 Mr. Pehl spent 11 years at Celgene Corporation, serving as General Manager Germany, Vice President Central Europe, Head of Hematology Europe and subsequently as Head of Global Marketing and finally as President of Hematology & Oncology. Previously, Mr. Pehl served 14 years at Amgen, Inc., where he held various commercial leadership positions in oncology, rheumatology and nephrology in Germany and for Amgen Europe in Switzerland. Mr. Pehl received a Diploma in Molecular Biology from Ludwig-Maximilians-University Munich, Germany. - Michael Pehl在血液学和肿瘤学方面拥有超过20年的经验，并在该领域推出了多款重磅药物，包括Revlimid，Pomalyst和Abraxane。在2017年12月加入Immunomedics之前，Pehl先生在新基医药公司工作了11年，担任德国总经理，Vice President中欧，血液学欧洲主管，随后担任全球营销主管，最后担任血液学和肿瘤学总裁。此前，他曾任职Amgen公司14年，在那里他曾担任德国肿瘤学、风湿病和肾脏学以及瑞士Amgen Europe公司的多种商业领导职务。Pehl先生在德国慕尼黑大学（Ludwig-Maximilians-University Munich）获得分子生物学文凭。
- Michael Pehl has more than 20 years of experience in hematology and oncology and has launched multiple blockbuster drugs in that space including Revlimid, Pomalyst, and Abraxane. Prior to joining Immunomedics in December 2017 Mr. Pehl spent 11 years at Celgene Corporation, serving as General Manager Germany, Vice President Central Europe, Head of Hematology Europe and subsequently as Head of Global Marketing and finally as President of Hematology & Oncology. Previously, Mr. Pehl served 14 years at Amgen, Inc., where he held various commercial leadership positions in oncology, rheumatology and nephrology in Germany and for Amgen Europe in Switzerland. Mr. Pehl received a Diploma in Molecular Biology from Ludwig-Maximilians-University Munich, Germany.
- Khalid Islam
-
Khalid Islam，在制药行业有着超过22年的经验。从1999年到2008年，他担任Arpida AG（瑞士证交所上市的抗感染公司）的总裁兼首席执行官。加入Arpida公司之前，他曾担任Hoechst Marion Roussel（全球制药公司）、Marion-Merrell Dow公司（全球制药公司）的多种研发职务。他是几家公司的创始人之一，此前曾担任Arpida AG（位于瑞士）、Rheoscience A / S（位于丹麦）的董事会成员，以及Arpida公司的主席。此外，他是C10 Pharma公司（位于挪威，巴黎风险资本集团Kurma Biofund公司的顾问）的董事会现任主席、the Network of Excellence in Pathogenomics的国际科学顾问委员会的成员，以及Current Drug Discovery and Technologies的编辑部成员。他持有伦敦大学切尔西学院（Chelsea College, University of London）的学士学位，以及伦敦帝国理工学院（Imperial College, University of London）的哲学博士学位。他在科学期刊上发表了超过80篇文章，拥有众多的专利。
Khalid Islam cofounded Gain Therapeutics, Inc. in 2017 and has served as Chairman of the Board since 2017. He is currently the Chairman of the Board of Fennec Pharmaceuticals Inc. and Minoryx Therapeutics S.L. From 2009 to 2014, Dr. Islam also served as Chairman and Chief Executive Officer of Gentium S.p.A, where, under his leadership, Defitelio was granted marketing authorization and the company nt from a $25 million valuation to a $1 billion all cash merger with Jazz Pharmaceuticals plc. From 1999 to 2008, he served as President and Chief Executive Officer of Arpida AG, where he transitioned the early stage startup to a SWX listed company and raised $300 million beten their initial public offering and follow ons. From 1987 to 1999, Dr. Islam held vario positions at HMR & MMD (now Sanofi Aventis). Prior to HMR & MMD, he worked in academia at Imperial College, University of London and Milan University, where he was a contract professor. He has also previoly served as a director of Immunomedics Inc., Karolinska Development, MolMed S.p.A., OxThera AB, Rheoscience AS, PCovery AS, Adenium AS and C10 Pharma AS. He is an advisor to Kurma Biofund (Paris) and Indaco Ventures (Milan). Dr. Islam is a graduate of Chelsea College and received his Ph.D. from Imperial College, University of London. - Khalid Islam，在制药行业有着超过22年的经验。从1999年到2008年，他担任Arpida AG（瑞士证交所上市的抗感染公司）的总裁兼首席执行官。加入Arpida公司之前，他曾担任Hoechst Marion Roussel（全球制药公司）、Marion-Merrell Dow公司（全球制药公司）的多种研发职务。他是几家公司的创始人之一，此前曾担任Arpida AG（位于瑞士）、Rheoscience A / S（位于丹麦）的董事会成员，以及Arpida公司的主席。此外，他是C10 Pharma公司（位于挪威，巴黎风险资本集团Kurma Biofund公司的顾问）的董事会现任主席、the Network of Excellence in Pathogenomics的国际科学顾问委员会的成员，以及Current Drug Discovery and Technologies的编辑部成员。他持有伦敦大学切尔西学院（Chelsea College, University of London）的学士学位，以及伦敦帝国理工学院（Imperial College, University of London）的哲学博士学位。他在科学期刊上发表了超过80篇文章，拥有众多的专利。
- Khalid Islam cofounded Gain Therapeutics, Inc. in 2017 and has served as Chairman of the Board since 2017. He is currently the Chairman of the Board of Fennec Pharmaceuticals Inc. and Minoryx Therapeutics S.L. From 2009 to 2014, Dr. Islam also served as Chairman and Chief Executive Officer of Gentium S.p.A, where, under his leadership, Defitelio was granted marketing authorization and the company nt from a $25 million valuation to a $1 billion all cash merger with Jazz Pharmaceuticals plc. From 1999 to 2008, he served as President and Chief Executive Officer of Arpida AG, where he transitioned the early stage startup to a SWX listed company and raised $300 million beten their initial public offering and follow ons. From 1987 to 1999, Dr. Islam held vario positions at HMR & MMD (now Sanofi Aventis). Prior to HMR & MMD, he worked in academia at Imperial College, University of London and Milan University, where he was a contract professor. He has also previoly served as a director of Immunomedics Inc., Karolinska Development, MolMed S.p.A., OxThera AB, Rheoscience AS, PCovery AS, Adenium AS and C10 Pharma AS. He is an advisor to Kurma Biofund (Paris) and Indaco Ventures (Milan). Dr. Islam is a graduate of Chelsea College and received his Ph.D. from Imperial College, University of London.
- Peter Barton Hutt
-
Peter Barton Hutt，他是食品及药物管理局（Food and Drug Administration，FDA）的前任首席顾问，并于2005年5月成为董事。他目前担任Covington & Burling公司的华盛顿特区的律师事务所的高级顾问，专注于食品和药品法。他自1994年起在哈佛法学院（Harvard Law School）教一门食品和药品法课程，并于1998年在斯坦福法学院（ Stanford Law School）教授同一门课程。他也是《Food and Drug Law：Cases and Materials》的合著者。他是医学研究所（Institute Of Medicine） （IOM）和美国国家科学院（National Academy of Sciences）（NAS）的成员。他最近任职美国总统科学和技术顾问委员会（PCAST）的创新药物开发和评估工作组。他也曾任职各种各样的学术和顾问委员会，包括国家卫生研究所（National Institutes of Health）（NIH）的行政重组小组。此前，他曾任职the IOM的执行委员会、NIH的咨询委员会、NAS的生物医学和行为科学研究训练委员会、批准癌症和艾滋病新药的审查当前程序的全国委员会（应布什总统的要求美国国家癌症研究所创立的）。他持有耶鲁大学（Yale University）的学士学位，以及哈佛大学（Harvard University）和纽约大学（New York University）的法律学位。他目前担任BIND Therapeutics公司和Momenta Pharmaceuticals公司的董事。此前，他曾担任Ista Parmaceuticals公司的董事（从2002年到2012年），以及Celera公司的董（从2008年到2011年）。
Peter Barton Hutt has served as a member of our board of directors since March 2012. Mr. Hutt has practiced law at Covington & Burling LLP, specializing in food and drug law, since 1960 except for the period from 1971 to 1975. From 1971 to 1975 he was Chief Counsel for the U.S. Food and Drug Administration. Mr. Hutt is a member of the board of directors of Flex Pharma, Inc. (Nasdaq: FLKS), Q Therapeutics, Inc. (Nasdaq: QCEL), Concert Pharmaceuticals, Inc. (Nasdaq: CNCE), and Immunomedics, Inc. (Nasdaq: IMMU), each of which is a public biotechnology company, as well as numerous private companies. During the last five years, Mr. Hutt also served as a member of the board of directors of BIND Therapeutics, Inc. (Nasdaq: BIND), Seres Therapeutics, Inc. (Nasdaq: MCRB), Xoma Ltd. (Nasdaq: XOMA), DBV Technologies SA (Nasdaq: DBVT), Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), and Evelo Biosciences, Inc. (Nasdaq: EVLO). Mr. Hutt received a B.A. from Yale University, an LL.B. from Harvard Law School, and an LL.M. from New York University School of Law. - Peter Barton Hutt，他是食品及药物管理局（Food and Drug Administration，FDA）的前任首席顾问，并于2005年5月成为董事。他目前担任Covington & Burling公司的华盛顿特区的律师事务所的高级顾问，专注于食品和药品法。他自1994年起在哈佛法学院（Harvard Law School）教一门食品和药品法课程，并于1998年在斯坦福法学院（ Stanford Law School）教授同一门课程。他也是《Food and Drug Law：Cases and Materials》的合著者。他是医学研究所（Institute Of Medicine） （IOM）和美国国家科学院（National Academy of Sciences）（NAS）的成员。他最近任职美国总统科学和技术顾问委员会（PCAST）的创新药物开发和评估工作组。他也曾任职各种各样的学术和顾问委员会，包括国家卫生研究所（National Institutes of Health）（NIH）的行政重组小组。此前，他曾任职the IOM的执行委员会、NIH的咨询委员会、NAS的生物医学和行为科学研究训练委员会、批准癌症和艾滋病新药的审查当前程序的全国委员会（应布什总统的要求美国国家癌症研究所创立的）。他持有耶鲁大学（Yale University）的学士学位，以及哈佛大学（Harvard University）和纽约大学（New York University）的法律学位。他目前担任BIND Therapeutics公司和Momenta Pharmaceuticals公司的董事。此前，他曾担任Ista Parmaceuticals公司的董事（从2002年到2012年），以及Celera公司的董（从2008年到2011年）。
- Peter Barton Hutt has served as a member of our board of directors since March 2012. Mr. Hutt has practiced law at Covington & Burling LLP, specializing in food and drug law, since 1960 except for the period from 1971 to 1975. From 1971 to 1975 he was Chief Counsel for the U.S. Food and Drug Administration. Mr. Hutt is a member of the board of directors of Flex Pharma, Inc. (Nasdaq: FLKS), Q Therapeutics, Inc. (Nasdaq: QCEL), Concert Pharmaceuticals, Inc. (Nasdaq: CNCE), and Immunomedics, Inc. (Nasdaq: IMMU), each of which is a public biotechnology company, as well as numerous private companies. During the last five years, Mr. Hutt also served as a member of the board of directors of BIND Therapeutics, Inc. (Nasdaq: BIND), Seres Therapeutics, Inc. (Nasdaq: MCRB), Xoma Ltd. (Nasdaq: XOMA), DBV Technologies SA (Nasdaq: DBVT), Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), and Evelo Biosciences, Inc. (Nasdaq: EVLO). Mr. Hutt received a B.A. from Yale University, an LL.B. from Harvard Law School, and an LL.M. from New York University School of Law.
高管简历
中英对照 | 中文 | 英文- Kurt Andrews
Kurt Andrews自2013年7月加入Valeritas起，Kurt Andrews曾担任公司人力资源副总裁。加入Valeritas之前，2004年至2013年7月他是 PTC Therapeutics（一家生物技术公司）人力资源副总裁，领导该公司的人力资源、信息技术和设施的功能。此外，2002年至2004年Andrews 先生是Vitex（一家生物技术公司）的人力资源董事，1996年至2002年在Applera Corporation（一家生物技术公司）逐步担任人力资源的领导角色，支持 Applied Biosystems 和Celera Genomics的增长。Andrews 先生获得了来自厄巴纳 - 尚佩恩University of Illinois劳动与雇佣关系研究院的文学硕士学位和厄巴纳 - 尚佩恩University of Illinois的学士学位。
Kurt Andrews has served as the Company's Chief Human Resources Officer since September 2018. Mr. Andrews was Sr. Vice President, Human Resources at Amicus Therapeutics from February 2016 to July 2018. Prior to Amicus, Mr. Andrews was the Vice President, Human Resources at Valeritas, Inc. from July 2013 to February 2016. Mr. Andrews holds a M.A. degree from the School of Labor and Employment Relations and a B.A. degree from the College of Liberal Arts and Sciences at University of Illinois at Urbana-Champaign.- Kurt Andrews自2013年7月加入Valeritas起，Kurt Andrews曾担任公司人力资源副总裁。加入Valeritas之前，2004年至2013年7月他是 PTC Therapeutics（一家生物技术公司）人力资源副总裁，领导该公司的人力资源、信息技术和设施的功能。此外，2002年至2004年Andrews 先生是Vitex（一家生物技术公司）的人力资源董事，1996年至2002年在Applera Corporation（一家生物技术公司）逐步担任人力资源的领导角色，支持 Applied Biosystems 和Celera Genomics的增长。Andrews 先生获得了来自厄巴纳 - 尚佩恩University of Illinois劳动与雇佣关系研究院的文学硕士学位和厄巴纳 - 尚佩恩University of Illinois的学士学位。
- Kurt Andrews has served as the Company's Chief Human Resources Officer since September 2018. Mr. Andrews was Sr. Vice President, Human Resources at Amicus Therapeutics from February 2016 to July 2018. Prior to Amicus, Mr. Andrews was the Vice President, Human Resources at Valeritas, Inc. from July 2013 to February 2016. Mr. Andrews holds a M.A. degree from the School of Labor and Employment Relations and a B.A. degree from the College of Liberal Arts and Sciences at University of Illinois at Urbana-Champaign.
- Michael Pehl
Michael Pehl在血液学和肿瘤学方面拥有超过20年的经验，并在该领域推出了多款重磅药物，包括Revlimid，Pomalyst和Abraxane。在2017年12月加入Immunomedics之前，Pehl先生在新基医药公司工作了11年，担任德国总经理，Vice President中欧，血液学欧洲主管，随后担任全球营销主管，最后担任血液学和肿瘤学总裁。此前，他曾任职Amgen公司14年，在那里他曾担任德国肿瘤学、风湿病和肾脏学以及瑞士Amgen Europe公司的多种商业领导职务。Pehl先生在德国慕尼黑大学（Ludwig-Maximilians-University Munich）获得分子生物学文凭。
Michael Pehl has more than 20 years of experience in hematology and oncology and has launched multiple blockbuster drugs in that space including Revlimid, Pomalyst, and Abraxane. Prior to joining Immunomedics in December 2017 Mr. Pehl spent 11 years at Celgene Corporation, serving as General Manager Germany, Vice President Central Europe, Head of Hematology Europe and subsequently as Head of Global Marketing and finally as President of Hematology & Oncology. Previously, Mr. Pehl served 14 years at Amgen, Inc., where he held various commercial leadership positions in oncology, rheumatology and nephrology in Germany and for Amgen Europe in Switzerland. Mr. Pehl received a Diploma in Molecular Biology from Ludwig-Maximilians-University Munich, Germany.- Michael Pehl在血液学和肿瘤学方面拥有超过20年的经验，并在该领域推出了多款重磅药物，包括Revlimid，Pomalyst和Abraxane。在2017年12月加入Immunomedics之前，Pehl先生在新基医药公司工作了11年，担任德国总经理，Vice President中欧，血液学欧洲主管，随后担任全球营销主管，最后担任血液学和肿瘤学总裁。此前，他曾任职Amgen公司14年，在那里他曾担任德国肿瘤学、风湿病和肾脏学以及瑞士Amgen Europe公司的多种商业领导职务。Pehl先生在德国慕尼黑大学（Ludwig-Maximilians-University Munich）获得分子生物学文凭。
- Michael Pehl has more than 20 years of experience in hematology and oncology and has launched multiple blockbuster drugs in that space including Revlimid, Pomalyst, and Abraxane. Prior to joining Immunomedics in December 2017 Mr. Pehl spent 11 years at Celgene Corporation, serving as General Manager Germany, Vice President Central Europe, Head of Hematology Europe and subsequently as Head of Global Marketing and finally as President of Hematology & Oncology. Previously, Mr. Pehl served 14 years at Amgen, Inc., where he held various commercial leadership positions in oncology, rheumatology and nephrology in Germany and for Amgen Europe in Switzerland. Mr. Pehl received a Diploma in Molecular Biology from Ludwig-Maximilians-University Munich, Germany.
- Usama Malik
Usama Malik自2017年8月起担任公司首席商务官，并于2018年8月被任命为公司临时首席财务官。加入公司之前，Malik自2013年1月起担任InnoAction Advisory Services（一家精品咨询公司，客户涉及制药和医疗技术领域）创始人和管理合伙人。在加入InnoAction之前，Malik先生于2011年12月至2012年12月担任Bridgewater Associates的高级管理人员，并于2007年11月至2011年11月担任辉瑞公司战略与创新全球Vice President。此前，Malik先生曾在战略咨询公司担任领导职务，包括Booz&Co.和毕马威咨询公司（KPMG Consulting），就企业战略，财务和业务转型机会为执行团队和董事会提供建议。
Usama Malik has served as the Company’s Chief Business Officer since August 2017 and was appointed the Company's Interim Chief Financial officer in August 2018. Prior to joining the Company, Mr. Malik was the founder and managing partner of InnoAction Advisory Services, a boutique advisory firm with clients in the pharmaceutical and medical technologies fields, since January 2013. Prior to InnoAction, Mr. Malik was part of Senior Management at Bridgewater Associates from December 2011 to December 2012 and served as the Global Vice President of Strategy and Innovation at Pfizer from November 2007 through November 2011. Previously, Mr. Malik served in leadership roles at strategy consulting firms including Booz & Co. and KPMG Consulting, advising executive teams and boards on corporate strategy, finance, and business transformation opportunities.- Usama Malik自2017年8月起担任公司首席商务官，并于2018年8月被任命为公司临时首席财务官。加入公司之前，Malik自2013年1月起担任InnoAction Advisory Services（一家精品咨询公司，客户涉及制药和医疗技术领域）创始人和管理合伙人。在加入InnoAction之前，Malik先生于2011年12月至2012年12月担任Bridgewater Associates的高级管理人员，并于2007年11月至2011年11月担任辉瑞公司战略与创新全球Vice President。此前，Malik先生曾在战略咨询公司担任领导职务，包括Booz&Co.和毕马威咨询公司（KPMG Consulting），就企业战略，财务和业务转型机会为执行团队和董事会提供建议。
- Usama Malik has served as the Company’s Chief Business Officer since August 2017 and was appointed the Company's Interim Chief Financial officer in August 2018. Prior to joining the Company, Mr. Malik was the founder and managing partner of InnoAction Advisory Services, a boutique advisory firm with clients in the pharmaceutical and medical technologies fields, since January 2013. Prior to InnoAction, Mr. Malik was part of Senior Management at Bridgewater Associates from December 2011 to December 2012 and served as the Global Vice President of Strategy and Innovation at Pfizer from November 2007 through November 2011. Previously, Mr. Malik served in leadership roles at strategy consulting firms including Booz & Co. and KPMG Consulting, advising executive teams and boards on corporate strategy, finance, and business transformation opportunities.
- Robert Iannone
Robert Iannone自2018年3月起担任公司研发主管和首席医疗官，在加入公司之前，Iannone博士于2014年7月至2018年4月受聘于阿斯利康，担任高级副总裁和免疫肿瘤学主管，全球药物开发和全球产品Vice President。在加入阿斯利康（AstraZeneca）之前，Iannone博士于2004年至2017年在默克（Merck）担任职务，职责不断增加，最终担任肿瘤临床开发执行董事兼部门主管。Iannone博士是一名儿科医生和儿科血液学家-肿瘤学家。Iannone博士毕业于美国天主教大学（Catholic University of America’；89），是耶鲁医学院（Yale Medical School）的红衣主教吉本斯学者（’；94）。
Robert Iannone was appointed to Board of Directors in June 2023. Since May 2019, he has served as the Executive Vice President, Global Head of Research and Development at Jazz Pharmaceuticals plc, and as their Chief Medical Officer from December 2019 until October 2021. From April 2018 until May 2019, Dr. Iannone served as Head of Research and Development and Chief Medical Officer of Immunomedics, Inc., a biopharmaceutical company. Prior to that, from July 2014 to April 2018, Dr. Iannone served in the roles of Senior Vice President and Head of Immuno oncology, Global Medicines Development and the Global Products Vice President at AstraZeneca plc, a global science led biopharmaceutical company. From 2004 to 2014, Dr. Iannone served in management roles at Merck Co., Inc., a global biopharmaceutical company, culminating in his role as Executive Director and Section Head of Oncology Clinical Development. From 2001 to 2004, he served as Assistant Professor of Pediatrics and from 2004 to 2012 as Adjunct Assistant Professor of Pediatrics at the University of Pennsylvania School of Medicine. Dr. Iannone has served on the board of directors of iTeos Therapeutics, Inc., a clinical stage biopharmaceutical company, since May 2021, and on the Cancer Steering Committee of the Foundation for the National Institutes of Health since 2011. He also served as a director of Jounce Therapeutics, Inc., a clinical stage immunotherapy company, between January 2020 and its acquisition by Concentra Biosciences in May 2023. Dr. Iannone received a B.S. from The Catholic University of America, an M.D. from Yale University and an M.S.C.E. from University of Pennsylvania and completed his residency in Pediatrics and fellowship in Pediatric Hematology Oncology at Johns Hopkins University.- Robert Iannone自2018年3月起担任公司研发主管和首席医疗官，在加入公司之前，Iannone博士于2014年7月至2018年4月受聘于阿斯利康，担任高级副总裁和免疫肿瘤学主管，全球药物开发和全球产品Vice President。在加入阿斯利康（AstraZeneca）之前，Iannone博士于2004年至2017年在默克（Merck）担任职务，职责不断增加，最终担任肿瘤临床开发执行董事兼部门主管。Iannone博士是一名儿科医生和儿科血液学家-肿瘤学家。Iannone博士毕业于美国天主教大学（Catholic University of America’；89），是耶鲁医学院（Yale Medical School）的红衣主教吉本斯学者（’；94）。
- Robert Iannone was appointed to Board of Directors in June 2023. Since May 2019, he has served as the Executive Vice President, Global Head of Research and Development at Jazz Pharmaceuticals plc, and as their Chief Medical Officer from December 2019 until October 2021. From April 2018 until May 2019, Dr. Iannone served as Head of Research and Development and Chief Medical Officer of Immunomedics, Inc., a biopharmaceutical company. Prior to that, from July 2014 to April 2018, Dr. Iannone served in the roles of Senior Vice President and Head of Immuno oncology, Global Medicines Development and the Global Products Vice President at AstraZeneca plc, a global science led biopharmaceutical company. From 2004 to 2014, Dr. Iannone served in management roles at Merck Co., Inc., a global biopharmaceutical company, culminating in his role as Executive Director and Section Head of Oncology Clinical Development. From 2001 to 2004, he served as Assistant Professor of Pediatrics and from 2004 to 2012 as Adjunct Assistant Professor of Pediatrics at the University of Pennsylvania School of Medicine. Dr. Iannone has served on the board of directors of iTeos Therapeutics, Inc., a clinical stage biopharmaceutical company, since May 2021, and on the Cancer Steering Committee of the Foundation for the National Institutes of Health since 2011. He also served as a director of Jounce Therapeutics, Inc., a clinical stage immunotherapy company, between January 2020 and its acquisition by Concentra Biosciences in May 2023. Dr. Iannone received a B.S. from The Catholic University of America, an M.D. from Yale University and an M.S.C.E. from University of Pennsylvania and completed his residency in Pediatrics and fellowship in Pediatric Hematology Oncology at Johns Hopkins University.
- Morris Rosenberg
Morris Rosenberg自2018年1月起担任公司首席技术官。在加入公司之前，Rosenberg博士于2012年6月至2018年1月在整个生物技术行业提供工艺开发和生物制剂制造方面的咨询服务。在咨询之前，Rosenberg博士曾在Seattle Genetics担任多个职位，最近的职位是从2009年2月到2012年6月担任流程科学执行Vice President。2004年10月至2009年2月发展Vice President。Rosenberg博士持有D.SC.St.Louis市Washington University化学工程学士学位。他还持有St.Louis市Washington University化学工程硕士学位和B.S.学位。
Morris Rosenberg has served as the Company's Chief Technology Officer since January 2018. Prior to joining the Company, Dr. Rosenberg provided consulting services across the Biotechnology industry in process development and biologics manufacturing from June 2012 to January 2018. Prior to his consulting, Dr. Rosenberg held various roles with Seattle Genetics, most recently as the Executive Vice President, Process Sciences from February 2009 to June 2012 and prior was the Sr. Vice President of Development from October 2004 to February 2009. Dr. Rosenberg holds a D.Sc. in Chemical Engineering from Washington University in St. Louis. He also holds both a M.S and a B.S. in Chemical Engineering from Washington University in St. Louis.- Morris Rosenberg自2018年1月起担任公司首席技术官。在加入公司之前，Rosenberg博士于2012年6月至2018年1月在整个生物技术行业提供工艺开发和生物制剂制造方面的咨询服务。在咨询之前，Rosenberg博士曾在Seattle Genetics担任多个职位，最近的职位是从2009年2月到2012年6月担任流程科学执行Vice President。2004年10月至2009年2月发展Vice President。Rosenberg博士持有D.SC.St.Louis市Washington University化学工程学士学位。他还持有St.Louis市Washington University化学工程硕士学位和B.S.学位。
- Morris Rosenberg has served as the Company's Chief Technology Officer since January 2018. Prior to joining the Company, Dr. Rosenberg provided consulting services across the Biotechnology industry in process development and biologics manufacturing from June 2012 to January 2018. Prior to his consulting, Dr. Rosenberg held various roles with Seattle Genetics, most recently as the Executive Vice President, Process Sciences from February 2009 to June 2012 and prior was the Sr. Vice President of Development from October 2004 to February 2009. Dr. Rosenberg holds a D.Sc. in Chemical Engineering from Washington University in St. Louis. He also holds both a M.S and a B.S. in Chemical Engineering from Washington University in St. Louis.
- Brendan P. Delaney
BrendanP.Delaney自2017年11月起担任公司首席商务官。在加入公司之前，Brendan于2011年3月至2018年11月受聘于Celgene，最近担任美国商业血液学/肿瘤学Vice President。在Celgene之前的职位包括全球营销、血液学Vice President和多发性骨髓瘤专营权全球营销执行董事。2011年加入Celgene公司之前，他曾担任Novartis Oncology公司的全球慢性粒细胞白血病CML特许经营董事。Brendan从2006年到2011年在Novartis Oncology担任多个商业职位，包括担任肾细胞癌Afinitor上市美国营销主管。Brendan在Rutgers University获得生物科学学士学位，在New York University Stern School of Business获得金融工商管理硕士学位。
Brendan P. Delaney has served as the Company's Chief Commercial Officer since November 2017. Prior to joining the Company, Brendan was employed at Celgene from March 2011 to November 2018 most recently holding the role of Vice President, U.S. Commercial Hematology/Oncology. Prior roles at Celgene include Vice President, Global Marketing, Hematology and Executive Director, Global Marketing, Multiple Myeloma Franchise. Before joining Celgene in 2011 he was the Director of the Global Chronic Myeloid Leukemia CML Franchise at Novartis Oncology. From 2006 to 2011 Brendan held a variety of commercial positions at Novartis Oncology, including serving as U.S. Marketing Lead for the launch of Afinitor in Renal Cell Carcinoma. Brendan received his B.S. in biological sciences from Rutgers University and his M.B.A. in finance from The Stern School of Business at New York University.- BrendanP.Delaney自2017年11月起担任公司首席商务官。在加入公司之前，Brendan于2011年3月至2018年11月受聘于Celgene，最近担任美国商业血液学/肿瘤学Vice President。在Celgene之前的职位包括全球营销、血液学Vice President和多发性骨髓瘤专营权全球营销执行董事。2011年加入Celgene公司之前，他曾担任Novartis Oncology公司的全球慢性粒细胞白血病CML特许经营董事。Brendan从2006年到2011年在Novartis Oncology担任多个商业职位，包括担任肾细胞癌Afinitor上市美国营销主管。Brendan在Rutgers University获得生物科学学士学位，在New York University Stern School of Business获得金融工商管理硕士学位。
- Brendan P. Delaney has served as the Company's Chief Commercial Officer since November 2017. Prior to joining the Company, Brendan was employed at Celgene from March 2011 to November 2018 most recently holding the role of Vice President, U.S. Commercial Hematology/Oncology. Prior roles at Celgene include Vice President, Global Marketing, Hematology and Executive Director, Global Marketing, Multiple Myeloma Franchise. Before joining Celgene in 2011 he was the Director of the Global Chronic Myeloid Leukemia CML Franchise at Novartis Oncology. From 2006 to 2011 Brendan held a variety of commercial positions at Novartis Oncology, including serving as U.S. Marketing Lead for the launch of Afinitor in Renal Cell Carcinoma. Brendan received his B.S. in biological sciences from Rutgers University and his M.B.A. in finance from The Stern School of Business at New York University.
- Jared Freedberg
Jared Freedberg自2018年9月起担任公司总法律顾问。在加入公司之前，Freedberg先生于2016年12月至2018年9月在Mallinckrodt担任法律Vice President。在加入Mallinckrodt之前，Freedberg先生于2014年11月至2016年11月担任Covance的业务开发和战略Vice President，并于2008年3月至2014年11月担任Covance的助理总法律顾问Vice President。Freedberg先生拥有宾夕法尼亚大学（University of Pennsylvania）的学士学位和杜克大学法学院（Duke University School of Law）的法学博士学位。
Jared Freedberg has served as the Company's General Counsel since September 2018. Prior to joining the Company, Mr. Freedberg was Vice President, Legal at Mallinckrodt from December 2016 to September 2018. Prior to Mallinckrodt, Mr. Freedberg was the Vice President, Business Development and Strategy at Covance from November 2014 to November 2016 and Vice President, Associate General Counsel at Covance from March 2008 to November 2014. Mr. Freedberg holds a B.A. degree from the University of Pennsylvania and a Juris Doctor degree from the Duke University School of Law.- Jared Freedberg自2018年9月起担任公司总法律顾问。在加入公司之前，Freedberg先生于2016年12月至2018年9月在Mallinckrodt担任法律Vice President。在加入Mallinckrodt之前，Freedberg先生于2014年11月至2016年11月担任Covance的业务开发和战略Vice President，并于2008年3月至2014年11月担任Covance的助理总法律顾问Vice President。Freedberg先生拥有宾夕法尼亚大学（University of Pennsylvania）的学士学位和杜克大学法学院（Duke University School of Law）的法学博士学位。
- Jared Freedberg has served as the Company's General Counsel since September 2018. Prior to joining the Company, Mr. Freedberg was Vice President, Legal at Mallinckrodt from December 2016 to September 2018. Prior to Mallinckrodt, Mr. Freedberg was the Vice President, Business Development and Strategy at Covance from November 2014 to November 2016 and Vice President, Associate General Counsel at Covance from March 2008 to November 2014. Mr. Freedberg holds a B.A. degree from the University of Pennsylvania and a Juris Doctor degree from the Duke University School of Law.